Aptar Pharma has announced the launch of the Twister capsule-based dry powder inhaler. The new DPI is intended to provide a cost-effective dry powder alternative to metered dose inhalers (MDIs), especially in the third world, the company says, with the aim of permitting “a wider range of asthma sufferers to not only gain better access to medication but also become more compliant with the treatment they receive due to its feedback design.”
According to Aptar, the Twister has been validated as an off-the-shelf device capable of delivering a wide range of formulations, and the device has both visual and audible feedbacks to provide confirmation of dose delivery. Design of the DPI took place in both France and China, and manufacturing will take place in Aptar’s Suzhou, China manufacturing facility, which currently makes pMDI valves and spray pumps.
Aptar Pharma Prescription Division Associate Director of Business Development Adam M. Shain commented, “Twister complements Aptar Pharma’s fully comprehensive range of drug delivery solutions, available worldwide for the pharmaceutical industry’s treatment of Asthma and COPD. Prohaler opened the door and taught us a lot about the world of DPIs. With the launch of Twister, Aptar Pharma is set to fulfill regional needs for a simpler and well suited solution to deliver powder to the lungs.”
Read the Aptar Pharma press release.
